image
Healthcare - Medical - Healthcare Information Services - NASDAQ - US
$ 14.47
2.26 %
$ 2.34 B
Market Cap
-180.87
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one CERT stock under the worst case scenario is HIDDEN Compared to the current market price of 14.5 USD, Certara, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one CERT stock under the base case scenario is HIDDEN Compared to the current market price of 14.5 USD, Certara, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one CERT stock under the best case scenario is HIDDEN Compared to the current market price of 14.5 USD, Certara, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart CERT

image
$15.0$15.0$14.0$14.0$13.0$13.0$12.0$12.0$11.0$11.0$10.0$10.0$9.0$9.0Nov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 Apr
FINANCIALS
385 M REVENUE
8.70%
-1.73 M OPERATING INCOME
95.75%
-12.1 M NET INCOME
78.23%
80.5 M OPERATING CASH FLOW
-2.77%
-112 M INVESTING CASH FLOW
-41.25%
-21 M FINANCING CASH FLOW
-122.40%
100 M REVENUE
5.84%
6 M OPERATING INCOME
131.42%
6.58 M NET INCOME
579.72%
49.4 M OPERATING CASH FLOW
190.63%
-97.2 M INVESTING CASH FLOW
-1664.03%
-1.3 M FINANCING CASH FLOW
76.75%
Balance Sheet Certara, Inc.
image
Current Assets 311 M
Cash & Short-Term Investments 179 M
Receivables 102 M
Other Current Assets 29.5 M
Non-Current Assets 1.26 B
Long-Term Investments 0
PP&E 16 M
Other Non-Current Assets 1.25 B
11.38 %6.49 %79.25 %Total Assets$1.6b
Current Liabilities 146 M
Accounts Payable 3.5 M
Short-Term Debt 8.31 M
Other Current Liabilities 134 M
Non-Current Liabilities 370 M
Long-Term Debt 22.3 M
Other Non-Current Liabilities 348 M
26.00 %4.32 %67.39 %Total Liabilities$516.4m
EFFICIENCY
Earnings Waterfall Certara, Inc.
image
Revenue 385 M
Cost Of Revenue 155 M
Gross Profit 231 M
Operating Expenses 232 M
Operating Income -1.73 M
Other Expenses 10.3 M
Net Income -12.1 M
400m400m350m350m300m300m250m250m200m200m150m150m100m100m50m50m00(50m)(50m)385m(155m)231m(232m)(2m)(10m)(12m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
59.88% GROSS MARGIN
59.88%
-0.45% OPERATING MARGIN
-0.45%
-3.13% NET MARGIN
-3.13%
-1.14% ROE
-1.14%
-0.77% ROA
-0.77%
-0.08% ROIC
-0.08%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Certara, Inc.
image
90m90m80m80m70m70m60m60m50m50m40m40m30m30m20m20m10m10m0020192019202020202021202120222022202320232024202420252025
Net Income -12.1 M
Depreciation & Amortization 68 M
Capital Expenditures -1.62 M
Stock-Based Compensation 34.8 M
Change in Working Capital 0
Others 2.4 M
Free Cash Flow 78.8 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Certara, Inc.
image
Wall Street analysts predict an average 1-year price target for CERT of $15 , with forecasts ranging from a low of $13 to a high of $16 .
CERT Lowest Price Target Wall Street Target
13 USD -10.16%
CERT Average Price Target Wall Street Target
15 USD 3.66%
CERT Highest Price Target Wall Street Target
16 USD 10.57%
Price
Max Price Target
Min Price Target
Average Price Target
18181717161615151414131312121111101099Jun '24Jun '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 6
6. Ownership
Insider Ownership Certara, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
638 K USD 2
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
3 Momentum Stocks That Could Soar Post-Market Volatility While the impact of unanticipated tariff policy changes in early April was market-wide, the recovery has been less even. Despite a major rebound following the sell-off, some firms have been sluggish to reclaim lost ground. marketbeat.com - 1 week ago
Certara Unveils $100 Million Buyback Plan In Better-Than-Expected Preliminary Earnings Report Certara, Inc. CERT on Monday announced expected revenue and bookings for the first quarter. benzinga.com - 2 weeks ago
Certara Launches Non-Animal Navigator™ Solution to Help Drug Developers Reduce Reliance on Animal Testing RADNOR, Pa., April 14, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced the launch of its Non-Animal Navigator™ solution designed to help biopharmaceutical companies lead the transition ignited by the FDA's Roadmap to Reducing Animal Testing in Preclinical Safety Studies. globenewswire.com - 2 weeks ago
Buy Certara After The FDA Announcement The FDA's phase-out of animal testing for monoclonal antibody therapies boosts Certara's growth prospects, as evidenced by a 15% stock jump. Certara's recently posted a 14.1% revenue increase Y/Y, with significant contributions from biosimulation and Chemaxon businesses. Certara's cautious AI investments align with the FDA's regulatory changes, enhancing its end-to-end biosimulation offerings from drug discovery to clinical trials. seekingalpha.com - 3 weeks ago
Certara (CERT) Soars 8.0%: Is Further Upside Left in the Stock? Certara (CERT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road. zacks.com - 3 weeks ago
What's Going On With Charles River, Certara, Simulations Plus Stocks On Friday? The U.S. Food and Drug Administration announced a major shift in how monoclonal antibody therapies and other drugs are evaluated, emphasizing a transition from traditional animal testing. benzinga.com - 3 weeks ago
Certara Expands the Simcyp™ Simulator Platform Advancing Biopharmaceutics, Drug-Drug Interaction & Biologic Capabilities RADNOR, Pa., April 01, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, has released a new version of the Simcyp™ Simulator for physiologically-based pharmacokinetic (PBPK) modeling. globenewswire.com - 1 month ago
Certara Appoints Dr. Adrian McKemey as President of Drug Development Solutions RADNOR, Pa., March 05, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced the appointment of Adrian McKemey, Ph.D. globenewswire.com - 1 month ago
Certara, Inc. (CERT) Q4 2024 Earnings Call Transcript Certara, Inc. (NASDAQ:CERT ) Q4 2024 Earnings Conference Call February 26, 2025 5:00 PM ET Company Participants David Deuchler - Investor Relations, Gilmartin Group LLC William Feehery - Chief Executive Officer John Gallagher - Chief Financial Officer Conference Call Participants Jeff Garro - Stephens Inc. Michael Cherny - Leerink Partners Christine Rains - William Blair David Windley - Jefferies Constantine Davides - Citizens Securities Andrew Moss - Bank of America Kyle Crews - UBS Operator Good day, and thank you for standing by. Welcome to the Certara Fourth Quarter 2024 Earnings Conference Call. seekingalpha.com - 2 months ago
Certara, Inc. (CERT) Surpasses Q4 Earnings and Revenue Estimates Certara, Inc. (CERT) came out with quarterly earnings of $0.15 per share, beating the Zacks Consensus Estimate of $0.13 per share. This compares to earnings of $0.09 per share a year ago. zacks.com - 2 months ago
Certara Reports Fourth Quarter 2024 Financial Results RADNOR, Pa., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today reported its financial results for the fourth quarter and full year 2024. globenewswire.com - 2 months ago
8. Profile Summary

Certara, Inc. CERT

image
COUNTRY US
INDUSTRY Medical - Healthcare Information Services
MARKET CAP $ 2.34 B
Dividend Yield 0.00%
Description Certara, Inc. provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access. It offers medicines to patients using biosimulation software, technology, and services to transform drug discovery and development. The company also provides related technology-enabled services to guide its customers' new drugs through the regulatory submission process and into the market. Its technology-enabled services include mechanistic biosimulation, empirical biosimulation, drug development and regulatory strategy, clinical pharmacology, model-based meta-analysis, regulatory writing and medical communications, regulatory operations, and market access. Further, company offers software, comprising mechanistic biosimulation platform, empirical PK/PD biosimulation platform, data standardization and compliance software, scientific informatics platform, clinical outcomes databases for biosimulation, authoring and management of regulatory submissions platform, and market access communication platform. The company serves biopharmaceutical companies, and academic and government institutions. It has operations in the United States, Canada, Spain, Luxembourg, Portugal, the United Kingdom, Germany, France, the Netherlands, Denmark, Switzerland, Italy, Poland, Japan, the Philippines, India, Australia, and China. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.
Contact 100 Overlook Center, Princeton, NJ, 08540 https://www.certara.com
IPO Date Dec. 11, 2020
Employees 1487
Officers Ms. Rona Anhalt Chief Human Resources Officer Dr. Frederic Yves Bois Ph.D., Pharm.D. Senior Scientific Advisor, Head of Mechanistic Modeling & Member of Simcyp Advisory Board Ms. Sheila Rocchio MBA Chief Marketing Officer Mr. Leif E. Pedersen President & Chief Commercial Officer Mr. Ron DiSantis Senior Vice President of Corporate Development Mr. Daniel D. Corcoran Senior Vice President & General Counsel Mr. John E. Gallagher III SVice President, Principal Accounting Officer & Chief Financial Officer Dr. Robert P. Aspbury Ph.D. President of Certara Scientific Software Dr. David Mitchell Ph.D. Senior Vice President of Strategic Engagement Dr. William F. Feehery Ph.D. Chief Executive Officer & Director